ID
15502
Description
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00151086
Link
https://clinicaltrials.gov/show/NCT00151086
Keywords
Versions (1)
- 6/1/16 6/1/16 -
Uploaded on
June 1, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Prostate Cancer NCT00151086
Eligibility Prostate Cancer NCT00151086
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI-1
- C0680251
Description
vinca alkaloid-based cytotoxic chemotherapy
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0042672
- UMLS CUI [1,2]
- C0392920
- UMLS CUI [2]
- C1522449
Description
brain metastasis
Data type
boolean
Alias
- UMLS CUI [1]
- C0220650
Description
spinal cord compression
Data type
boolean
Alias
- UMLS CUI [1]
- C0037926
Description
prior malignancy
Data type
boolean
Alias
- UMLS CUI [1]
- C0006826
Description
preexisting neuropathy
Data type
boolean
Alias
- UMLS CUI [1]
- C0442874
Description
active gastrointestinal disease
Data type
boolean
Alias
- UMLS CUI [1]
- C0017178
Similar models
Eligibility Prostate Cancer NCT00151086
- StudyEvent: Eligibility
C1513041 (UMLS CUI [1,2])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
C0392920 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2])